HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Benzinga · 11/06/2023 11:40
HC Wainwright & Co. analyst Ed Arce reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $6 price target.